Scientific Industries Announces Industry Veteran, John Nicols, as New Board Member and Chairman of Scientific Bioprocessing Inc.

BOHEMIA, NY / ACCESSWIRE / March 8, 2024 / Scientific Industries, Inc. ("SI") (OTCQB:SCND) announced the appointment of John Nicols to the Board of Directors of SI and Chairman of its wholly, owned subsidiary, Scientific Bioprocessing Inc. ("SBI"), effective March 4, 2024. Mr. Nicols replaces Mr. John A. Moore as Chairman of SBI.

John A. Moore, Chairman of SI, said "We are grateful for the contribution that Mr. Nicols has made to our Company since becoming a strategic advisor in September 2023, representing the voice of the customer in our Bioprocessing business segment. Mr. Nicols brings extensive industry experience and we look forward to his wisdom and skillset that will enhance our Board and further our strategy for the successful commercialization of our innovative DOTS platform."

Mr. Nicols commented: "It's been exciting getting to know SI's team and technology, and I'm honored to join the Board and Chair the SBI subsidiary. It's become increasingly clear to me the disruptive potential and uniqueness of SBI's DOTS platform. Enabling the ‘humble' shake flask to generate the range of critical fermentation data equivalent to much more expensive bioreactors is going to fuel the increasingly beneficial application of artificial intelligence tools to help liberate a major bottleneck constraining the enormous potential for synthetic biology to take over global manufacturing supply chains."

Mr. John Nicols brings over three decades of experience in delivering sustained growth and value creation across diverse global businesses, from cutting-edge biotechnologies to traditional chemistry. He is the former president and CEO of Codexis, where he led the growth and transformation of Codexis into a leading synthetic biology company. From 2013 to 2022, Nicols grew Codexis' product sales nine-fold to exceed $100 million, commercializing dozens of new products across pharmaceutical, food and nutrition, and life science tools verticals. Prior to Codexis, Nicols held various executive roles spanning his 22 years at Albemarle Corp, where he grew their largest business unit to more than $1 billion in global sales. Nicols received a M.B.A. from the Massachusetts Institute of Technology and a B.S. degree in chemical engineering from the Polytechnic Institute of New York University. Mr. Nicols is a NACD Director Certified Board partner, and he currently serves as Chair of both Antheia, a synthetic biology-based producer for the pharmaceutical industry, and Solve M.E., a leading not-for-profit seeking cures for debilitating infection associated chronic diseases like ME/CFS and Long Covid.